A recently published study including 55 isocitrate-dehydrogenase-wild type glioma patients with uni- or bilateral corpus callosum infiltration treated in the time-period between 2005 and 2017 demonstrated an increase of 2-year survival rate from 7% of biopsied patients to 30% of patients with tumor resection. This evidence concerns the gene IDH3A and glioma.